PENTOBARBITAL SODIUM (pentobarbital sodium) by Sagent Pharmaceuticals is clinical pharmacology barbiturates are capable of producing all levels of cns mood alteration from excitation to mild sedation, to hypnosis, and deep coma. First approved in 2016.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia. Barbiturates depress the sensory cortex,…
Worked on PENTOBARBITAL SODIUM at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.